Sorrento's CCO decamps for a startup; Amgen selling off CO facility;

@FierceBiotech: Bristol-Myers flags an early success for PhIII Opdivo study. Article | Follow @FierceBiotech

@JohnCFierce: Americans want Medicare to negotiate lower drug prices -- (one day it's going to come). More from Reuters | Follow @JohnCFierce

> George Uy, Sorrento Therapeutics ($SRNE) chief commercial officer, is leaving the company to serve as CEO of an unnamed startup. More

> Amgen ($AMGN) is selling off a 692,000-square-foot facility in Colorado, part of cost-cutting effort announced last year through which the company will shed about 430 jobs in the area. News

> Alynlam ($ALNY) has kicked off an open-label extension study for patisiran, a rare disease therapy now in Phase III development. The company expects to report final data next year and submit the treatment for FDA approval in 2017. Item

Medical Device News

@FierceMedDev: Illumina launches new lab service for HiSeq X sequencing systems. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study finds Philips' ventilator helps reduce hospital readmissions for COPD. Article | Follow @VarunSaxena2

@EmilyWFierce: In 10 years, liquid biopsy test for cancer will be part of routine annual exams, says Guardant Health CEO. More from the WSJ | Follow @EmilyWFierce

> Hospitals launch trial to test AliveCor's iPhone-enabled ECG for diagnosis of heart attacks. Report

> Early study results indicate EndoStim's implant is effective for treating acid reflux. Story

> Stryker to buy Turkish partner in its second hospital bed acquisition in 2015. More

> NIH-backed scientists develop wireless, remote-controlled brain implant. Article

Pharma News

@FiercePharma: We've got a brand new special report today! Top 10 pharma companies in social media. Feature | Follow @FiercePharma

@EricPFierce: ICYMI: Gallant Pharma owner notified in jail by FDA he is disbarred for life from the pharma industry. More from PharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Baxalta tots up winning hemophilia data as new med beats Advate in late-stage trial. More from FiercePharmaMarketing | Follow @CarlyHFierce

> India expands drug pricing with caps for two antibiotics. Story

> Vast majority of consumers want Medicare to negotiate drug prices. Article

> Sanofi preps for 'profitable' dengue vaccine rollout in 20 countries. Report

Animal Health News

> KC Animal Health Corridor investment forum slated for early September. More

> Aratana charts positive results for canine pain drug, predicts 2016 launch. Report

> PetCure spots booming market for radiosurgery in pets with cancer. Story

> Valeant steps into animal health with $800M acquisition of Egypt's Amoun. Article

> Virbac charts strong sales growth, nabs Big Pharma veteran to oversee quality. Item

Biotech IT News

> FDA turns to Google for help spotting adverse events. Report

> Vermillion raises $18.8M to fund escalation of bioinformatics ambitions. News

> Illumina wraps lab automation and software around HiSeq X to lower barrier to mass sequencing. Article

> Report: Danaher nears $30M buyout of computer-aided imaging business. More

> Arivale sets up with $36M, A-list founders and one eye on the R&D potential of its 'dense data clouds.' Story

Pharma Marketing News

> Does high TV ad rotation give patients the wrong idea about drugs? More

> Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer. Item

> AstraZeneca ponies up for heart-attack patients with new Vida Health app. Report

> VC to pharma: Better get on board with digital health marketing. Story

> Lilly adds new Coco the Type 1 monkey tale to its Disney bookshelf. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.